Halozyme Therapeutics Director Sells $568K Under Rule 10b5-1 Plan

Insider Transaction Analysis: Halozyme Therapeutics, Inc. (HALO)

Overview

On October 1, 2026, Director Matthew L. Posard sold a cumulative total of 5,230 shares of Halozyme Therapeutics Common Stock across four open-market transactions, generating gross proceeds of approximately $567,753.34. The transactions brought his direct beneficial ownership from 58,839 shares down to 53,609 shares.

Transaction Breakdown

• 730 shares sold at a weighted average price of $107.168 (range: $106.930 - $107.660)
• 3,300 shares sold at a weighted average price of $108.454 (range: $107.990 - $108.930)
• 1,100 shares sold at a weighted average price of $109.569 (range: $109.040 - $109.970)
• 100 shares sold at a price of $110.040

Key Context & Governance

• 10b5-1 Trading Plan: As indicated in footnote F1, all sales were executed under a pre-established Rule 10b5-1 trading plan adopted on June 15, 2026. This pre-scheduled nature significantly reduces any implication of opportunistic or material non-public information-driven selling.
• Position Impact: The sale represents an 8.9% reduction in Mr. Posard's direct holdings, leaving him with a substantial remaining stake of 53,609 shares.
• Significance: Rated Low due to the modest size relative to overall company capitalization, the execution pursuant to a scheduled Rule 10b5-1 plan, and the director retaining over 91% of his direct holdings.